↓ Skip to main content

Omalizumab for asthma in adults and children

Overview of attention for article published in Cochrane database of systematic reviews, January 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
67 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
300 Dimensions

Readers on

mendeley
368 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Omalizumab for asthma in adults and children
Published in
Cochrane database of systematic reviews, January 2014
DOI 10.1002/14651858.cd003559.pub4
Pubmed ID
Authors

Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters, Parameswaran Nair

Abstract

Asthma is a respiratory (airway) condition that affects an estimated 300 million people worldwide and is associated with significant morbidity and mortality. Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E (IgE). It is called an 'anti-IgE' drug. IgE is an immune mediator involved in clinical manifestations of asthma. A recent update of National Institute for Health and Care Excellence (NICE) guidance in 2013 recommends omalizumab for use as add-on therapy in adults and children over six years of age with inadequately controlled severe persistent allergic IgE-mediated asthma who require continuous or frequent treatment with oral corticosteroids.

Twitter Demographics

The data shown below were collected from the profiles of 67 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 368 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 <1%
Japan 2 <1%
Tunisia 1 <1%
Mexico 1 <1%
South Africa 1 <1%
Ecuador 1 <1%
Unknown 360 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 64 17%
Student > Bachelor 53 14%
Researcher 44 12%
Student > Ph. D. Student 41 11%
Student > Doctoral Student 28 8%
Other 90 24%
Unknown 48 13%
Readers by discipline Count As %
Medicine and Dentistry 190 52%
Agricultural and Biological Sciences 25 7%
Nursing and Health Professions 21 6%
Biochemistry, Genetics and Molecular Biology 15 4%
Psychology 12 3%
Other 42 11%
Unknown 63 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 53. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 February 2019.
All research outputs
#366,667
of 14,388,923 outputs
Outputs from Cochrane database of systematic reviews
#949
of 10,946 outputs
Outputs of similar age
#6,546
of 259,968 outputs
Outputs of similar age from Cochrane database of systematic reviews
#15
of 172 outputs
Altmetric has tracked 14,388,923 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,946 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.9. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 259,968 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 172 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.